Australian private health insurance margins remain resilient, but competition and product downgrading pressures persist

Overview

This report focuses on the key issues for Medibank Private Ltd. (MPL.AX) and NIB Holdings (NHF.AX) ahead of their FY26 results announcements. Goldman Sachs's central view is that although the Australian private health insurance industry continues to face competition, customer downgrading, affordability pressure following premium increases and hospital cost inflation, both MPL and NHF have tools to maintain net margins through expense ratios, product design, claims benefits from downgrading and capital management.

Core views

The core views are: First, resident health insurance industry growth remained robust through Mar-26, with hospital insurance policyholders up 2.5% over 12 months and general ancillary coverage up 2.2%, but higher premiums and cost-of-living pressure make the outlook for 2H26 and FY27 more important. Second, MPL faces more pronounced market-share pressure, with FYTD resident PH growth below the industry and aggregator-channel competition driving higher churn. Third, MPL and NHF net margins may remain broadly stable from FY26 to FY27, with MPL benefiting from expense-ratio leverage, claims benefits from product downgrading and MPL Health growth, while NHF relies more on cost savings, New Zealand recovery and international business repricing. Fourth, strong capital positions mean future M&A, Tier 2 financing, capital returns or capital management following the sale of the travel business could all provide potential upside.

Analysis framework

The report uses a pre-results outlook and valuation-update framework, combining APRA industry data, company 3Q26 updates, 1H26 margins and claims inflation data, FY26 guidance, capital adequacy, business-segment operating trends and target-price roll-forward analysis to compare MPL and NHF on margin resilience, growth quality and relative valuation.

Methodology notes

• Pre-results outlookKey-variable review ahead of FY26 results

  Assess short-term risk and return based on growth, claims inflation, expense ratios, capital and segment updates ahead of the FY26 results announcements.

  The report tracks key variables ahead of MPL's August 20, 2026 results and NHF's August 24, 2026 results, including resident PH growth, downgrading, claims inflation, ARHI net margins, New Zealand recovery, MPL Health contribution and capital management.

• Margin analysisComparison of net effective premium rates and claims inflation

  Compare the net effective premium rate after adjusting premium increases for downgrading with claims inflation and expense-ratio changes to determine whether margins can remain stable.

  MPL's average FY26 headline premium increase was approximately 4.27%; after deducting 1.5% downgrading, the net effective rate was approximately 2.77%, close to the midpoint claims inflation estimate of 2.75%. NHF's average FY26 headline premium increase was approximately 5.7%; after deducting 1.3% downgrading, the net effective rate was approximately 4.4%, matching potential underlying claims inflation of approximately 4.4%.

• Relative valuationComparison of MPL and NHF ratings and target prices

  Compare valuation multiples, growth sources, capital returns and margin risks under similar industry pressures.

  Goldman Sachs maintains MPL at Neutral, viewing its approximately 20x valuation as broadly neutral; it maintains NHF at Buy, believing its approximately 15x valuation, New Zealand recovery and capital management offer a better risk-reward profile.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Medibank Private Ltd. (MPL.AX)

  Covered company, rated Neutral

  Strengths

  Stable PHI net margins, MPL Health FY30 growth target, potential release of A$250m in APRA capital, M&A and Tier 2 financing capacity, and potential reduction in cybercrime costs.

  Weaknesses

  Resident PH growth below the industry, aggregator-channel competition and customer churn pressure, and limited apparent attractiveness at approximately 20x valuation.

  Comparison

  Relative to NHF, MPL has a larger business and clearer MPL Health growth, but also a higher valuation and more pronounced market-share pressure.

  Risks

  Claims inflation above expectations, intensified product downgrading, regulatory impacts on the benefit ratio and age-based rebate adjustments, Healthscope developments and hospital indexation pressure.

• NIB Holdings (NHF.AX)

  Covered company, rated Buy

  Strengths

  Approximately 15x valuation, New Zealand business recovery, international business repricing, ARHI expense-ratio improvement and potential capital management following the sale of the travel business.

  Weaknesses

  Higher 1H26 claims inflation, removal of PH growth guidance, and the impact of NDIS regulatory changes on Thrive, including a decline in participant numbers.

  Comparison

  Relative to MPL, Goldman Sachs has a stronger preference for NHF's valuation and recovery potential, although segment volatility and claims inflation require further validation.

  Risks

  New Zealand growth affected by high prices, persistent ARHI claims inflation, deterioration in Thrive earnings and participant trends, and capital management falling short of expectations.

• Australian private health insurance industry

  Industry backdrop and primary revenue pool for both companies

  Strengths

  Through Mar-26, participation in both hospital and general ancillary insurance improved by 0.2 percentage points; hospital participation reached 45.8% and general ancillary participation 55.5%.

  Weaknesses

  Higher premiums, cost-of-living pressure, aggregator-channel competition and downgrading may weigh on growth and the revenue mix.

  Comparison

  Overall industry growth remains stronger than MPL's recent resident growth, highlighting differences in company-level competition and channel strategies.

  Risks

  Regulatory scrutiny of the benefit ratio, changes to age-based rebates, hospital wage and indexation costs, and the outcome of Healthscope's disposal.

Key data

• MPL target priceA$5.0012-month target price raised from A$4.75, reflecting changes to net investment income and MPL Health forecasts.
• NHF target priceA$8.0012-month target price raised from A$7.60; although earnings were revised slightly lower, valuation roll-forward supports the higher target price.
• MPL ratingNeutralAt approximately 20x valuation, Goldman Sachs views the relative valuation as neutral.
• NHF ratingBuyAt approximately 15x valuation, Goldman Sachs has a stronger preference for NHF's valuation and growth recovery relative to MPL.
• Industry hospital insurance policyholder growth2.5%12-month growth through Mar-26, up from 2.3% through Dec-25.
• Industry general ancillary policyholder growth2.2%12-month growth through Mar-26, up from 2.1% through Dec-25.
• MPL FYTD resident PH growth1.1%Through Mar-26, below the industry level of approximately 1.8%, indicating market-share pressure.
• MPL 1H26 downgrading1.5%Goldman Sachs believes approximately 50bps may be related to growth investment and Live Better.
• NHF 1H26 downgrading1.3%Downgrading weighs on the revenue mix but may generate claims benefits.
• MPL FY26 claims inflation guidance2.6%-2.9%Claims inflation was 2.5% in 1H26; Goldman Sachs uses the midpoint of 2.75% to assess margins.
• NHF 1H26 underlying claims inflation4.1%Underlying figure excluding bed-rate changes, customer-benefit investment and risk-equalization volatility.
• MPL 1H26 capital position1.9x PCA, capital ratio 14.1%Above the 10%-12% target range, with additional capital supporting the A$250m APRA regulatory adjustment.
• NHF 1H26 capital position1.91x PCAThe target range is 1.5x-1.6x; healthy funds have A$244.6m of excess capital above minimum requirements.
• MPL Health FY30 target>A$200m earningsGrowth from A$76.7m in FY25 to more than A$200m by FY30, with targeted capital use of approximately A$700m.
• MPL 2H26E Underlying NPATA$336.5mGoldman Sachs forecast.
• NHF 2H26E UOPA$134.1mGoldman Sachs forecast.

Impact & implications

For investment implications, the report supports selective exposure to the Australian private health insurance sector: industry growth continues, but high premiums, economic pressure and competition make growth quality more important; margin resilience comes from premiums, expense ratios, claims benefits from downgrading and capital efficiency rather than volume growth alone. MPL's investment case is defensive and neutral, with focus on MPL Health and capital release; NHF is more attractive because of its lower valuation, New Zealand recovery and capital management optionality.

Risks

• Resident PH growth may slow in 2H26 or FY27, particularly following the Apr-26 premium increases and cost-of-living pressure.
• Product downgrading at MPL and NHF may remain elevated, weighing on the revenue mix in the short term and affecting growth quality.
• Hospital claims inflation and nurse wage increases may exceed the buffer provided by premium increases and cost savings.
• Regulatory risks include a continued rise in the benefit ratio, restrictions on product phoenixing, age-based rebate reform and discussions related to the National Efficient Price.
• Competition in MPL's aggregator channels and customer churn may continue to weigh on market share.
• If recovery in NHF's New Zealand, Thrive and Health Services segments falls short of expectations, the Buy thesis could weaken.
• Although the sale or restructuring of Healthscope is considered manageable, it could still affect hospital contracts and cost negotiations.

What to watch

• MPL FY26 results on August 20, 2026: focus on resident PH growth, FY27 growth outlook, claims inflation, MER and MPL Health contribution.
• NHF FY26 results on August 24, 2026: focus on ARHI net margins, New Zealand business margins, capital management following the Travel sale, and Thrive participant and earnings trends.
• Whether product downgrading improves from the elevated 1H26 levels of 1.5% for MPL and 1.3% for NHF, or deteriorates further due to interest-rate and affordability pressures.
• Whether industry policyholder growth, churn and participation remain resilient following the Apr-26 premium increases.
• Whether MPL Health continues to support the FY30 target of more than A$200m in earnings through approximately 30% operating-profit growth.
• Whether NHF's travel business sale is completed as planned by the end of 2026 and whether capital management is announced in 2H26.
• The impact of PHI age-based rebate reform from April 2027 on downgrading, lapses and risk mix among people aged over 65.